Skye Bioscience - About the company
Skye Bioscience is a public company based in San Diego (United States), founded in 2011. It operates as a Developer of cannabinoid-based therapies for the treatment of glaucoma and other diseases. Skye Bioscience has raised $1.97M in funding from Hilco Vision. The company has 117 active competitors, including 34 funded and 17 that have exited. Its top competitors include companies like Adocia, Carmot and Kailera.
Company Details
Developer of cannabinoid-based therapies for the treatment of glaucoma and other diseases. The lead candidate THCVHS is a prodrug of tetrahydrocannabinol, a topical formulation for the treatment of glaucoma and ocular hypertension. Another candidate CBDVHS is an analog of cannabidiol that has multiple therapeutic applications. These therapies work on the endocannabinoid system which sends chemical messages and triggers biological actions and helps in the treatment of diseases
- Website
- skyebioscience.com
- Social
- Email ID
- *****@skybioscience.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2011
Location
San Diego, United States
Stage
Public
Total Funding
$1.97M in 17 rounds
Latest Funding Round
Investors
Ranked
12th among 117 active competitors
Employee Count
17 as on Aug 31, 2026
Investment & Acquisitions
Exit Details
Public
Legal entities associated with Skye Bioscience
Skye Bioscience is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
SKYE BIOSCIENCE, INC. CIN: 1516551 , United States, Active | - | - | - | |
Skye Bioscience Inc CIN: 45-0692882 , United States, Active | Dec 31, 2010 | - | 11 (As on Dec 31, 2023) | - |
Skye Bioscience's IPO details
Skye Bioscience got listed on Nov 26, 2014.
Click here to take a look at Skye Bioscience's IPO in detail
Sign up to download Skye Bioscience's company profile
Skye Bioscience's funding and investors
Skye Bioscience has raised a total funding of $1.97M over 17 rounds. Its first funding round was on Nov 06, 2012. Skye Bioscience has 8 institutional investors.
Here is the list of recent funding rounds of Skye Bioscience:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 13, 2024 | 6926787 | Post IPO | 9255307 | 9762690 | 1655321 | 4688690 |
Jan 31, 2024 | 8952754 | Post IPO | 2394139 | 5272797 | 4184709 | |
Nov 01, 2018 | 6006202 | Post IPO | 9364970 | 3380716 | 7021117 | 2205620 |
Access funding benchmarks and valuations. Sign up today!View details of Skye Bioscience's funding rounds and investors
Skye Bioscience's founders and board of directors
Founder? Claim ProfileSkye Bioscience's employee count trend
Skye Bioscience has 17 employees as of Aug 26. Here is Skye Bioscience's employee count trend over the years:
Uncover Skye Bioscience's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Skye Bioscience's Competitors and alternates
Top competitors of Skye Bioscience include Adocia, Carmot and Kailera. Here is the list of Top 10 competitors of Skye Bioscience, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of therapeutics for the treatment of diabetes and obesity | $26M | 69/100 | ||
2nd | Carmot 2008, Berkeley (United States), Acquired | Developer of disease-modifying therapies to treat metabolic diseases | $386M | 66/100 | |
3rd | Kailera 2024, Waltham (United States), Public | Developer of therapies for treating obesity and related conditions | $1B | 65/100 | |
4th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
5th |  D&D Pharmatech 2014, Seongnam-si (South Korea), Public | Developer of GLP-1-based therapeutics for metabolic disease treatment | $205M | 64/100 | |
6th |  Enveda 2019, Boulder (United States), Series E | AI-based platform to decipher the chemistry of nature and develop new medicines | $845M | 63/100 | |
7th |  MBX Biosciences 2018, Carmel (United States), Public | Developer of drugs for the treatment of rare endocrine diseases | $216M | 61/100 | |
8th |  Metsera 2022, New York City (United States), Acquired | Biopharmaceutical company focusing on medicines for obesity and metabolic diseases | $505M | 61/100 | |
9th |  Congruence Therapeutics 2021, Montreal (Canada), Series B | Developer of therapeutics for the treatment of rare diseases | $136M | 60/100 | |
10th | Zealand Pharma 1998, Glostrup (Denmark), Public | Developer of protein therapies for the treatment of diabetes and gastrointestinal diseases | - | 59/100 | |
12th | Skye Bioscience 2011, San Diego (United States), Public | Developer of cannabinoid-based therapies for the treatment of glaucoma and other diseases | $1.97M | 57/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Skye Bioscience's competitors? Click here to see the top ones
Skye Bioscience's Investments and acquisitions
Skye Bioscience has acquired 2 companies including Bird Rock Bio and Bird Rock Bio. Skye Bioscience has not made any investments as of now.Reports related to Skye Bioscience
Here is the latest report on Skye Bioscience's sector:
News related to Skye Bioscience
Filter this listMedia has covered Skye Bioscience for a total of 17 events in the last 1 year, 5 of them have been about company updates and 1 about partnerships.
•
Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateGlobeNewswire•May 12, 2026•Skye Bioscience
•
Skye Bioscience Reports FY 2025 Financial Results and Business UpdateGlobeNewswire•Mar 11, 2026•Skye Bioscience
•
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud LawsuitPR Newswire•Jan 07, 2026•Rosenlegal, Skye Bioscience, Kuehn, Berger Montague and 4 others
•
Halozyme and Skye Bioscience Announce Global Collaboration to Evaluate Nimacimab Co-Formulated with ENHANZE® for ObesityGlobeNewswire•Jan 05, 2026•Skye Bioscience, Halozyme
•
Levi & Korsinsky Reminds Shareholders of Skye Bioscience, Inc. Lawsuit Lead Plaintiff DeadlinePR Newswire•Dec 23, 2025•Skye Bioscience, Levi & Korsinsky, Rosen Law Firm, Bronstein, Gewirtz & Grossman and 4 others
•
TLX Lawsuit Alert: The Gross Law Firm Notifies Telix Pharmaceuticals Ltd. Investors of Class ActionBenzinga•Dec 18, 2025•Securitiesclasslaw, Telix Pharma, Skye Bioscience, Levi & Korsinsky and 7 others
•
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DeFi TechnologiesPR Newswire•Dec 17, 2025•DeFi, Faruqi & Faruqi, Securitiesclasslaw, Kahn Swick & Foti and 13 others
•
Hagens Berman Investigates Primo Brands (PRMB) Over Alleged Merger Failure and CEO ReplacementPR Newswire•Dec 16, 2025•Primo Brands, Hagens Berman Sobol Shapiro, BlueTriton, Securitiesclasslaw and 2 others
•
Stride, Inc. Sued for Securities Law Violations; Investors Should Contact Levi & KorsinskyGlobeNewswire•Dec 16, 2025•Stride Health, Levi & Korsinsky, Stride, Skye Bioscience and 7 others
•
FISERV, INC. (NASDAQ: FISV) DEADLINE ALERT Bernstein Liebhard LLP Reminds Fiserv, Inc. Investors of Upcoming DeadlineGlobeNewswire•Dec 15, 2025•Fiserv, Bitdeer, Perrigo, Rosenlegal and 8 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Skye Bioscience
Explore our recently published companies
- Easy-Insurance - Unfunded company
- Dyimin - Unfunded company
- Turner - Horsforth based, 1946 founded, Acquired company
- Mergemiddleeast - Unfunded company
- Doro Beauty - Toronto based, Unfunded company
- Padula - West Chester based, 2017 founded, Unfunded company
